The benefit of thyroid hormone therapy for subclinical hypothyroidism is uncertain. New evidence from recent large randomized clinical trials warrants an update of previous meta-analyses.
S ubclinical hypothyroidism, defined as elevated thyrotropin in combination with normal-range free thyroxine, 1 is common. 2, 3 According to the NHANES III report, 4 an estimated 13 million people have subclinical hypothyroidism in the United States. The prevalence is higher in women and in older people. 2, 3 Subclinical hypothyroidism is often treated with thyroid hormones (levothyroxine), 5 particularly when it co-occurs with symptoms potentially attributable to hypothyroidism, such as tiredness, constipation, and unexplained weight gain.
5
Relatively limited evidence exists from randomized clinical trials (RCTs) to guide therapy of subclinical hypothyroidism. Systematic reviews have been inconclusive and clinical practice guidelines have varied regarding recommendations for managing subclinical hypothyroidism. [6] [7] [8] [9] [10] Two large randomized trials of levothyroxine therapy in patients with subclinical hypothyroidism were recently completed. 11, 12 This meta-analysis and systematic review incorporated recent trials and evaluated whether thyroid hormone therapy was associated with improved symptoms and other benefits in nonpregnant adults with subclinical hypothyroidism.
Methods
We followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement 13 and published the protocol of this systematic review in the PROSPERO database (identifier: CRD42017055536).
Eligibility Criteria, Literature Search, and Study Selection
We considered randomized trials that included nonpregnant adults with subclinical hypothyroidism. Subclinical hypothyroidism was defined as a thyrotropin level above the reference range in combination with a free thyroxine level within the reference range (according to center-specific reference ranges). The intervention had to consist of thyroid hormone therapy (triiodothyronine, thyroxine, or a combination of both) for at least 1 month, with a minimum follow-up of 3 months. The control group had to receive either placebo or no therapy. To be included, studies had to report quantitative data for at least 1 of the study's primary or secondary outcomes: general quality of life, thyroidrelated quality of life/hypothyroid symptoms, depressive symptoms, fatigue/tiredness, cognitive function, pain, muscle strength, blood pressure, body mass index, cardiovascular events (myocardial infarction, stroke, revascularization), mortality, or adverse effects (hyperthyroidism due to overdosing). Data had to be reported with effect estimates and measures of precision (standard deviations or standard errors). The primary outcomes were general quality of life and thyroid-related quality of life/hypothyroid symptoms, whereas depressive symptoms, fatigue/ tiredness, cognitive function, pain, muscle strength, blood pressure, body mass index, cardiovascular events, mortality, and adverse effects were secondary outcomes. Studies that included only patients with subclinical hypothyroidism in combination with another specific condition (eg, patients with diabetic nephropathy and subclinical hypothyroidism) were excluded because this type of study population is not representative of most patients with subclinical hypothyroidism. We excluded studies that exclusively enrolled pregnant women or women who wanted to become pregnant. Pseudorandomization (eg, pre-post comparisons) did not qualify for inclusion. We searched MEDLINE, EMBASE, Web of Science, Cochrane Library, CENTRAL, Emcare, and Academic Search Premier from inception until July 4, 2018, in cooperation with a trained librarian. Search terms were adapted according to the syntax of each specific database, and no language restrictions were applied. We searched trial registries on ClinicalTrials.gov for upcoming and not yet published trials on this research topic and asked authors for the status of the trial if not published yet. We screened references of key articles for additional potentially relevant articles. Details of the search strategy are presented in eAppendix 1 in Supplement 1.
Two researchers (M.S. and M.D.M.) evaluated eligibility independently based on titles and abstracts of all studies retrieved in the electronic search. Studies not excluded in this first step were independently assessed for inclusion after full-text evaluation by 2 reviewers (M.F. and M.S.). We manually screened bibliographies of the included studies as well as guidelines and review articles for additional studies. Discrepancies were resolved by consensus among the study team.
Data Extraction and Risk-of-Bias Assessment
A standard data extraction form was used, adapted from a template suggested by Cochrane (eAppendix 2 in Supplement 1).
14 Two researchers (M.S. and E.M.) independently extracted bibliographic details, funding source, eligibility criteria, information about the study population and setting, study design, risk of bias, intervention/control intervention, and results and independently evaluated the quality of evidence using the GRADE tool. 15 If a study reported more than 1 outcome measure for a specific outcome domain (eg, more than 1 cognition test to assess cognitive function), we chose measures that were most relevant to the largest number of patients, including international usage. This was determined by consensus among the study team. As an example, Parle et al 16 reported 5 different cognition tests. We analyzed results from the Mini-Mental State Examination because it is used worldwide and because it is a more general assessment of cognitive function than more specific alternative tests, such as the Trail Making Test. When a study mentioned an outcome of interest without providing estimates (eg, the study reported no difference in body mass index between the intervention and the control group without providing data on mean differences and standard deviations), we contacted the author for the data. If studies reported results for an outcome at multiple time points during the intervention (eg, body mass index at 6 and 12 months), only the most recent measurement was used in statistical analyses. Data were extracted in duplicate by 2 independent reviewers (M.S. and E.M.) and differences were resolved by consensus.
Statistical Analyses
Study results were presented separately for each outcome with estimates as reported in the original publication and transformed into standardized mean differences (SMDs) when different scales were used for the same outcome domain. We coded SMDs such that positive values indicated benefit of thyroid hormone therapy, with 0.2, 0.5, and 0.8 corresponding to small, moderate and large effects, respectively. 17 In contrast, for body mass index and blood pressure, negative values indicated a benefit of thyroid hormone therapy. For estimations of treatment effects, we used mean values and their standard deviations at the end of treatment in both groups, assuming balanced baseline values due to the randomized designs. For outcomes on which studies reported treatment effects at different time points, we included only the estimate at the most recent follow-up time point, thereby avoiding counting a study twice in a formal meta-analysis. Overall results were calculated using random-effects models unless fewer than 5 studies were included for a meta-analysis because in that case, the between-study variance could not be estimated reliably, so a fixed-effects analysis was performed. For better clinical interpretation, overall SMDs were also back-transformed to one original scale according to a method proposed by the Cochrane Collaboration 17 for general quality of life, thyroid-related quality of life/hypothyroid symptoms, depressive symptoms, cognitive function, and muscle strength. Heterogeneity was assessed visually with forest plots and quantified with I 2 (low: 0%-40%; moderate:
40%-75%; and high: >75%). If substantial heterogeneity existed and a sufficient number of publications was available (n = 10), we aimed to explore potential sources of heterogeneity in protocol prespecified subgroup analyses (eg, restricting the analysis to high-quality studies). In addition, a post hoc sensitivity analysis was performed with the aim to evaluate heterogeneity after excluding studies showing a statistically significant benefit of placebo treatment. If a sufficient number of publications was available (n = 10), publication bias was assessed via funnel plots (visually) and more formally with the Egger test. 18 Statistical significance testing was 2-sided and P<.05 was considered statistically significant. All analyses were conducted with Stata, release 14 (StataCorp).
Results
The systematic literature search retrieved 3086 studies, and 2 additional studies were retrieved after searching references of key articles. After removing 1438 duplicates, 2 reviewers (M.S. and M.D.M.) independently screened 1650 unique articles for potential eligibility based on title and abstract. Forty-nine potentially eligible studies were evaluated in full text independently by 2 reviewers (M.F. and M.S.). Among these, 25 studies did not meet the inclusion criteria. Three additional studies were excluded because of data presentation problems [19] [20] [21] ; for 2 of these articles, the authors indicated that data were no longer available 19, 20 ; for one, the author could not be reached 21 (eTable 1 in Supplement 1). Twenty-one studies met the inclusion criteria 11, 12, 16, [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] (eFigure in Supplement 1). Among the 21 studies, a total of 2192 adults were randomized (Table) . Study sizes ranged from 20 to 737 participants; mean ages ranged from 32 to 74 years; percentages of women ranged from 46% to 100%; and baseline mean thyrotropin values ranged from 4.4 to 12.8 mIU/L. Two studies (99 participants) had a mean baseline thyrotropin level greater than 10 mIU/L. 22, 23 Seven studies provided information about hypothyroid symptoms at baseline, and in these studies, the burden of symptoms was mild to moderate (Table) . 12, [22] [23] [24] [25] [26] [27] In the thyroid hormone therapy groups, mean thyrotropin levels at the end of follow-up ranged between 0.5 and 3.7 mIU/L (eTable 2 in Supplement 1), indicating that treatment was associated with normalization of thyrotropin levels. In contrast, mean thyrotropin in the placebo/no intervention groups remained elevated at the end of follow-up, ranging from 4.6 to 14.7 mIU/L (eTable 2). The duration of the intervention (thyroid hormone therapy or placebo/no therapy) ranged from 3 months to 18 months. Three studies compared thyroid hormone therapy with no intervention and the other studies compared thyroid hormone therapy with placebo. 11, 28, 29 Two studies were supported by industry (Table) .
22,30
Thyroid hormone therapy was not associated with benefit for either of the 2 primary outcomes. Four studies including 796 participants evaluated general quality of life (SMD, −0.11; 95% CI, −0.25 to 0.03; I 2 =66.7%) ( Figure 1) . 12, 26, 27, 31 It is estimated that on the Euro Quality of Life 5 Dimensions Questionnaire (range, −0.59 to 1.00; higher scores indicate better quality of life), this SMD would represent a difference of 0.02 (95% CI, −0.01 to 0.05) in favor of placebo. Four studies including 858 participants evaluated thyroid-related quality of life/hypothyroid symptoms (SMD, 0.01; 95% CI, −0.12 to 0.14; I 2 =0.0%) (Figure 1) . 12, 22, 31, 32 It is estimated that on the ThyPRO hypothyroid symptoms score (range, 0-100; higher scores indicate more hypothyroid symptoms), this SMD would represent a difference of 0.18 (95% CI, −2.10 to 2.45) in favor of levothyroxine. Similarly, thyroid hormone therapy was not ; in handgrip strength, this SMD would represent a difference of 1.12 kg (95% CI, −1.12 to 2.24 kg) in favor of levothyroxine. Systolic blood pressure (8 studies; 1372 participants) was −0.7 mm Hg (95% CI, −2.6 to 1.2 mm Hg; I 2 =0.0%) ( Figure 3) . 11, 12, 29, [32] [33] [34] [35] [36] Body mass index (calculated as weight in kilograms divided by height in meters squared) (15 studies; 1633 participants) was 0.2 (95% CI, −0.4 to 0.8; I 2 =45.5%) ( Figure 4) . 11, 12, 23, [27] [28] [29] [30] [32] [33] [34] [35] [36] [37] [38] [39] Only the TRUST trial (the largest included study, with 737 participants randomized) evaluated fatigue/tiredness, cardiovascular events, mortality, and adverse effects. 12 No beneficial or harmful association between thyroid hormone therapy and these outcomes was reported ( Figure 1 and eTables 2 and 4 in Supplement 1) . No study included pain as an outcome. Detailed results are summarized in eTables 2 and 4. Subgroup analyses were not performed because the number of studies for a single outcome was too small and/or there was low to moderate heterogeneity such that no exploration was indicated. The meta-analyses for general quality of life and body mass index showed moderate heterogeneity (I 2 =66.7% and I 2 =45.5%, respectively). Therefore, post hoc sensitivity analyses were performed excluding studies showing a statistically significant benefit of placebo. 23, 27, 30 Results remained similar, but hetero- .6%]). We did not formally assess publication bias. Based on the negative results, there was no indication that positive studies were published while negative studies remained unpublished.
The overall quality of the 21 included studies was good, with only 9 of 126 items judged to be at high risk of bias (eTable 3inSupplement 1); 2 trials had low risk of bias for all criteria, 12, 22 including the largest and most recent trial, 12 and only 1 trial, the second largest and second most recent, had a high risk of bias in 3 of 6 domains. 11 Accordingly, the quality of evidence assessed with the GRADE tool was high regarding the main outcomes of general quality of life and thyroid-related symptoms, as well as regarding muscle strength, blood pressure, and body mass index (eTable 4 in Supplement 1). The quality of evidence was moderate for depressive symptoms, fatigue/ tiredness, cognitive function, and adverse effects, whereas it was low for cardiovascular events and mortality (eTable 4).
Discussion
In this systematic review and meta-analysis of RCTs in nonpregnant adults with subclinical hypothyroidism, thyroid hormone therapy was not associated with benefit regarding general quality of life, thyroid-related symptoms, depressive symptoms, fatigue/tiredness, cognitive function, muscle strength, blood pressure, or body mass index. Compared with prior systematic reviews and metaanalyses published between 2007 8 and 2015, 9 this metaanalysis included 2 recent randomized trials, which were the largest trials published to date on this topic. 11, 12 Overall, the quality of evidence reported herein was moderate to high. Quality of evidence was high regarding the primary outcomes of this review (general quality of life and thyroid-related symptoms). Results of this review consistently demonstrated no association of thyroid replacement therapy with improved outcomes, including a relatively large number of diverse outcomes. Most outcomes, except cardiovascular events and mortality, had narrow confidence intervals. In addition, this meta-analysis focused on patient-centered outcomes such as quality of life and fatigue, which are the most common symptoms that prompt therapy in general practice.
56
Although current guidelines are at first sight cautious with treatment recommendations, more than 90% of persons with subclinical hypothyroidism and a thyrotropin level of less than 10 mIU/L would actually qualify for treatment.
6,10,57 However, results of this meta-analysis are not consistent with these guideline recommendations. In addition to absence of an association of thyroid hormone therapy with improved outcomes, thyroid hormone therapy is associated with adverse effects when overtreatment occurs.
5,58,59
Limitations This study has several limitations. First, the RCTs included in this meta-analysis used different questionnaires and/or tests for a given outcome in combination with different treatment durations (eg, 4 different cognitive tests in the 4 studies examining cognitive function, with treatment durations ranging from 3 to 18 months). However, little heterogeneity across the study results was observed except for general quality of life and body mass index. For these outcomes, heterogeneity resulted from 3 studies that showed a statistically significant benefit of placebo. 23, 27, 30 After excluding these studies in post hoc sensitivity analyses, thyroid hormone therapy remained unassociated with benefit for general quality of life and body mass index, and heterogeneity was lower. Therefore, it seems unlikely that this meta-analysis missed a potential beneficial association between thyroid hormone therapy and any outcome analyzed due to inappropriate pooling of overly heterogeneous studies. Second, only 1 RCT reported on major adverse cardiovascular events. Therefore, definitive evidence is lacking regarding the association of therapy for subclinical hypothyroidism with reduced cardiovascular event rates.
12 Third, RCTs that reported results only qualitatively were excluded from analyses. Fourth, mean thyrotropin values at baseline were less than 7.0 mIU/L in 11 of 21 included RCTs, and only 2 RCTs examined participants with a mean baseline thyrotropin level higher than 10 mIU/L. 22,23 Therefore, the current findings may not be generalizable to people with subclinical hypothyroidism and a thyrotropin level higher than 10 mIU/L. Fifth, the highest mean age in the included studies was 74 years. 12,16 Therefore, these results may not be generalizable to people older than 80 years. Sixth, only 7 of 21 trials (33%) reported hypothyroid symptoms at baseline, and the burden of symptoms was mild to moderate in these trials. The other 14 trials did not describe symptoms at baseline. It is possible that the subgroup of people with subclinical hypothyroidism and a high burden of symptoms would still benefit from treatment. Seventh, patients with subclinical hypothyroidism and "severe" symptoms of hypothyroidism may be underrepresented in clinical trials because they 
Conclusions
Among nonpregnant adults with subclinical hypothyroidism, the use of thyroid hormone therapy was not associated with improvements in general quality of life or thyroid-related symptoms. These findings do not support the routine use of thyroid hormone therapy in adults with subclinical hypothyroidism. e Upgrade of 1 as we consider it high quality evidence that thyroid hormone therapy does not confer benefit (downgrade was due to inconsistency, but the "outlier" 147 studies were in the direction of lower body-mass index under placebo). 148 f Downgrade 2 due to imprecision (results compatible with benefit as well as harm due to thyroid hormone therapy). Only one RCT reported on cardiovascular events 149 and mortality, and the mean follow-up was 17 months, too short to thoroughly examine these outcomes. This form can be used as a guide for developing your own data extraction form. Sections can be expanded 297 and added, and irrelevant sections can be removed. It is difficult to design a single form that meets the 298 needs of all reviews, so it is important to consider carefully the information you need to collect, and design 299 your form accordingly. Information included on this form should be comprehensive, and may be used in the 300 text of your review, 'Characteristics of included studies' table, risk of bias assessment, and statistical 301 analysis. 302
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Notes on using a data extraction form: 304  Be consistent in the order and style you use to describe the information for each included study.
305
 Record any missing information as unclear or not described, to make it clear that the information was not 306 found in the study report(s), not that you forgot to extract it. 307  Include any instructions and decision rules on the data collection form, or in an accompanying document. 308
It is important to practice using the form and give training to any other authors using the form. 309  You will need to protect the document in order to use the form fields (Tools / Protect document) 310 311 
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